Athenex

+1 716.898.86261001 Main Street, Suite 600, Buffalo, New York, 14203

Athenex

Improving the lives of cancer patients everywhere

Athenex acquires Kuur Therapeutics

LEARN MORE

A global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer

LEARN MORE

A deep innovative pipeline

LEARN MORE

Recent News

2022-01-12T08:30:00

Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility

2021-12-13T07:00:00

Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting

2021-11-30T08:00:00

Athenex to Host Key Opinion Leader Webinar on CAR-NKT Approach to Cancer

2021-11-29T08:00:00

Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

2021-11-22T08:00:00

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer at SABCS 2021

2021-11-18T08:00:00

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

2021-11-09T08:00:00

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mutated p53, KRAS, and EGFR for the Development of Autologous and Allogeneic Cell Therapies

2021-11-04T09:15:00

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at 63rd ASH Annual Meeting and Exposition

2021-11-04T07:00:00

Athenex Provides Third Quarter 2021 Corporate and Financial Update

Our Science

We are focused on discovering and developing novel therapies for treating cancer and addressing unmet medical needs.

Investors

View press releases, events and presentations, and other investment information

Join Our Team

As the Company grows, we are always looking to add talented professionals to join the Athenex family.